The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for managing obesity. Unlike some available weight loss treatments, retatrutide appears to provide a significant substantial reduction in body mass and improve metabolic function, pa